Cigna Group (NYSE:CI) Posts Quarterly Earnings Results, Beats Estimates By $0.22 EPS

30 Apr 2026, 21:22 by Amy Steele · The Cerbat Gem

Cigna Group (NYSE:CI – Get Free Report) posted its quarterly earnings data on Thursday. The health services provider reported $7.79 EPS for the quarter, beating the consensus estimate of $7.57 by $0.22, Zacks reports. Cigna Group had a net margin of 2.17% and a return on equity of 19.46%. The business had revenue of $68.52 billion during the quarter, compared to analyst estimates of $66.89 billion. During the same quarter last year, the firm posted $6.74 earnings per share. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. Cigna Group updated its FY 2026 guidance to 30.350- EPS.

Here are the key takeaways from Cigna Group’s conference call:

Strong Q1 results — total revenues of $68.5 billion and adjusted EPS of $7.79; management raised full‑year adjusted EPS guidance to at least $30.35, signaling confidence in execution and outlook.
Evernorth Specialty & Care Services outperformed — pre‑tax adjusted earnings rose ~20% driven by specialty volume growth, higher biosimilar/specialty‑generic adoption, and contribution from the Shields investment.
PBS transition and renewals weighed on near‑term results — Pharmacy Benefit Services pre‑tax adjusted earnings declined ~28% (about a $150 million year‑over‑year headwind) due to large client renewals and investments to build the rebate‑free Signature model.
Portfolio shaping announced — Cigna will exit the individual exchange at year‑end and is exploring strategic alternatives for eviCore; management says these moves are proactive and not expected to be material to capital recapture.
Leadership transition set for July 1 — Brian Evanko will become CEO (David Cordani to Executive Chair) with an emphasized focus on data, AI, affordability, and personalization as strategic priorities.

Cigna Group Stock Down 0.6%

CI stock traded down $1.74 during midday trading on Thursday, reaching $290.58. 2,412,433 shares of the company were exchanged, compared to its average volume of 1,339,993. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.74 and a current ratio of 0.74. Cigna Group has a 1-year low of $239.51 and a 1-year high of $350.00. The stock’s 50-day simple moving average is $274.24 and its 200 day simple moving average is $276.84. The company has a market cap of $76.58 billion, a price-to-earnings ratio of 13.10, a price-to-earnings-growth ratio of 1.01 and a beta of 0.26.

Cigna Group Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 18th. Shareholders of record on Thursday, June 4th will be issued a dividend of $1.56 per share. The ex-dividend date of this dividend is Thursday, June 4th. This represents a $6.24 dividend on an annualized basis and a yield of 2.1%. Cigna Group’s dividend payout ratio (DPR) is presently 28.13%.

Insider Buying and Selling

In other Cigna Group news, insider Nicole S. Jones sold 2,307 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $288.91, for a total transaction of $666,515.37. Following the sale, the insider owned 32,647 shares of the company’s stock, valued at approximately $9,432,044.77. This trade represents a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Everett Neville sold 1,719 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $288.91, for a total transaction of $496,636.29. Following the sale, the insider directly owned 5,670 shares in the company, valued at approximately $1,638,119.70. The trade was a 23.26% decrease in their position. The SEC filing for this sale provides additional information. 0.60% of the stock is currently owned by company insiders.

Institutional Trading of Cigna Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CI. Brighton Jones LLC raised its holdings in Cigna Group by 9.3% during the fourth quarter. Brighton Jones LLC now owns 3,736 shares of the health services provider’s stock worth $1,032,000 after purchasing an additional 318 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in Cigna Group by 10.4% during the second quarter. Sivia Capital Partners LLC now owns 1,160 shares of the health services provider’s stock worth $384,000 after purchasing an additional 109 shares in the last quarter. NewEdge Advisors LLC raised its holdings in Cigna Group by 4.5% during the second quarter. NewEdge Advisors LLC now owns 22,225 shares of the health services provider’s stock worth $7,347,000 after purchasing an additional 958 shares in the last quarter. Treasurer of the State of North Carolina grew its position in shares of Cigna Group by 16.6% during the second quarter. Treasurer of the State of North Carolina now owns 148,840 shares of the health services provider’s stock worth $49,204,000 after acquiring an additional 21,173 shares during the last quarter. Finally, Osterweis Capital Management Inc. purchased a new position in shares of Cigna Group during the second quarter worth approximately $163,000. Institutional investors and hedge funds own 86.99% of the company’s stock.

Cigna Group News Summary

Here are the key news stories impacting Cigna Group this week:

Positive Sentiment: Cigna beat Q1 earnings expectations and raised its FY‑2026 adjusted EPS outlook to at least $30.35, signaling stronger profitability than analysts expected. Cigna Q1 Earnings Beat Estimates
Positive Sentiment: Evernorth (Cigna’s health services/pharmacy-benefit unit) showed double‑digit revenue growth and drove margin/operational strength in the quarter, helping offset pharmacy cost pressures. Cigna Revenue Rises on Evernorth Growth
Positive Sentiment: Company press release and Reuters coverage confirm revenue beat (~$68.5B) and a slight upward tweak to the annual adjusted profit forecast — fundamentals support near‑term earnings visibility. Cigna Reports Strong Q1 & Raises Outlook
Neutral Sentiment: Market commentary and bullish research notes (Substack summaries, analyst price targets) reiterate long‑term upside based on valuation and diversified businesses, but these are opinions rather than new catalysts. Is CI a Good Stock to Buy?
Negative Sentiment: Cigna announced it will exit the Affordable Care Act individual market in 2027, affecting roughly 369,000 members — a near‑term subscriber loss and political/regulatory risk that likely pressured the stock. Cigna to Exit ACA Market
Negative Sentiment: Quiver/filings show large institutional reductions from some major managers in recent quarters, which could amplify selling pressure even after the beat. Quiver Quantitative CI Earnings & Holdings
Negative Sentiment: Analysts and reports note rising pharmacy costs; while Evernorth grew revenue, higher PBM/pharmacy expense remains a margin risk to monitor. PBM/Pharmacy Cost Commentary

Analysts Set New Price Targets

CI has been the topic of several analyst reports. Piper Sandler reduced their target price on shares of Cigna Group from $374.00 to $370.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Leerink Partners raised their target price on shares of Cigna Group from $270.00 to $297.00 and gave the company a “market perform” rating in a report on Friday, February 6th. Robert W. Baird reduced their target price on shares of Cigna Group from $315.00 to $306.00 and set an “outperform” rating on the stock in a report on Wednesday, April 15th. Sanford C. Bernstein raised shares of Cigna Group from a “market perform” rating to an “outperform” rating and raised their target price for the company from $307.00 to $358.00 in a report on Thursday, March 12th. Finally, Barclays reduced their target price on shares of Cigna Group from $305.00 to $303.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Cigna Group currently has an average rating of “Moderate Buy” and a consensus price target of $332.47.

Read Our Latest Stock Analysis on Cigna Group

About Cigna Group

(Get Free Report)

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.